Tisento Therapeutics
Clinical trials sponsored by Tisento Therapeutics, explained in plain language.
-
New hope for MELAS: experimental drug tested for Long-Term safety
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety of a daily oral drug called zagociguat in 44 adults with MELAS, a rare genetic disease that affects energy production in cells. All participants previously completed a lead-in study of the same drug. Researchers will monitor side effects…
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill aims to ease fatigue and brain fog in rare mitochondrial disease
Disease control OngoingThis Phase 2b trial tests an oral drug called zagociguat in 43 adults with MELAS syndrome, a rare genetic disorder that causes fatigue, muscle weakness, and stroke-like episodes. Participants take either 15 mg, 30 mg, or a placebo daily for 12 weeks. The study measures changes in…
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC